Dr. Samuele Cazzamalli is presenting “From DNA-encoded chemistry to ACP3-targeted radioligand therapeutics against prostate cancer”. In addition, Dr. Cristiano Pini will give an update on “Diagnostic Performance, Safety, and Pharmacokinetics of [⁶⁸Ga]Ga-OncoACP3 in Prostate Cancer – Preliminary Results from a Prospective Phase I Clinical Trial” and Prof. Philippp Backhaus will give a presentation on “Theranostic targeting of the prostatic acid phosphatase (ACP3) with [⁶⁸Ga]Ga-OncoACP3-DOTA and [¹⁷⁷Lu]Lu-OncoACP3-DOTA in prostate cancer patients”.

Moreover, Dr. Fabrizia Gelardi will present “First-in-Human Phase I Study of [⁶⁸Ga]Ga-OncoCAIX: Preliminary Results on Safety, Dosimetry, Pharmacokinetics, and Diagnostic Performance”.

Follow the link for more details